Jump to content

Budralazine

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by DMacks (talk | contribs) at 20:14, 13 November 2022 (evasion; all have at least some RS fail, and some are nothing but RS fail). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Budralazine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N-(4-methylpent-3-en-2-ylideneamino)phthalazin-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H16N4
Molar mass240.310 g·mol−1
3D model (JSmol)
  • n2nc(c1ccccc1c2)N/N=C(/C=C(\C)C)C

Budralazine (INN) is a vasodilator.[1][2]

References

[edit]
  1. ^ Akashi A, Chiba T, Suzuki I, Hashimoto H (September 1978). "Pharmacology of budralazine, a new antihypertensive drug". Archives Internationales de Pharmacodynamie et de Thérapie. 235 (1): 134–46. PMID 736687.
  2. ^ Yoshioka M, Minami M, Saito H (1991). "The anti-tachycardic mechanism of a direct-acting vasodilator, budralazine, in rats". Clinical and Experimental Hypertension, Part A. 13 (5): 1107–14. doi:10.3109/10641969109042116. PMID 1773498.


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Budralazine&oldid=1121721854"